Clinical Trials Directory

Trials / Completed

CompletedNCT01485692

Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation

Safety and Efficacy of Four Intramuscular Interventions for the Management of Acute Psychomotor Agitation

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
120 (actual)
Sponsor
University of Sao Paulo · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Not accepted

Summary

This study aims to evaluate the efficacy and safety of four options of medications in the management of acute psychomotor agitation,or violence and aggression situations in health services. All of the treatment options are already approved and currently used for this purpose. The options are: haloperidol plus midazolam, haloperidol plus promethazine, olanzapine and ziprasidone. The investigators hypothesized that all treatment options are effective in the treatment of acute agitation, but the combination haloperidol plus promethazine could elicit more adverse affects than the others.

Conditions

Interventions

TypeNameDescription
DRUGhaloperidol+promethazinehaloperidol, 2,5mg plus promethazine,25mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, in the 90 minutes period of observation
DRUGhaloperidol + midazolamhaloperidol, 2,5mg plus midazolam, 7,5 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
DRUGolanzapineolanzapine, 10mg, intramuscular injection, after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of observation
DRUGZiprasidoneziprasidone, 10 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation

Timeline

Start date
2009-02-01
Primary completion
2011-03-01
Completion
2011-03-01
First posted
2011-12-05
Last updated
2011-12-05

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT01485692. Inclusion in this directory is not an endorsement.